Skip to content
10-K

Annual Report

Vistagen Therapeutics, Inc. VTGN

0001628280-26-043271

← back to feed
Filed
Jun 15, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2026 · Jun 12, 2026 41.03M sh
Shares Diluted FY 2026 · Mar 31, 2026 38.07M sh
Shares Diluted FY 2026 · Mar 31, 2025 30.88M sh
Operating Cash Flow FY 2026 · Mar 31, 2026 −$66.44M
Operating Cash Flow FY 2026 · Mar 31, 2025 −$42.1M
Cash And Equivalents FY 2026 · Mar 31, 2026 $30.79M
Cash And Equivalents FY 2026 · Mar 31, 2025 $67.13M
Stockholders Equity FY 2026 · Mar 31, 2026 $35.52M
Stockholders Equity FY 2026 · Mar 31, 2025 $70.39M
Stockholders Equity FY 2026 · Mar 31, 2024 $114.29M
Current Liabilities FY 2026 · Mar 31, 2026 $12.8M
Current Liabilities FY 2026 · Mar 31, 2025 $12.61M
Total Liabilities FY 2026 · Mar 31, 2026 $13.04M
Total Liabilities FY 2026 · Mar 31, 2025 $13.95M
Current Assets FY 2026 · Mar 31, 2026 $46.94M
Current Assets FY 2026 · Mar 31, 2025 $82.08M
Total Assets FY 2026 · Mar 31, 2026 $48.56M
Total Assets FY 2026 · Mar 31, 2025 $84.34M
Eps Diluted FY 2026 · Mar 31, 2026 −$1.83
Eps Diluted FY 2026 · Mar 31, 2025 −$1.67
Eps Basic FY 2026 · Mar 31, 2026 −$1.83
Eps Basic FY 2026 · Mar 31, 2025 −$1.67
Sga Expense FY 2026 · Mar 31, 2026 $18.42M
Sga Expense FY 2026 · Mar 31, 2025 $17.08M
Rd Expense FY 2026 · Mar 31, 2026 $54.97M
Rd Expense FY 2026 · Mar 31, 2025 $39.38M
Net Income FY 2026 · Mar 31, 2026 −$69.69M
Net Income FY 2026 · Mar 31, 2025 −$51.42M
Operating Income FY 2026 · Mar 31, 2026 −$72.13M
Operating Income FY 2026 · Mar 31, 2025 −$55.97M